论文部分内容阅读
目的:了解15种常用抗菌药物对产超广谱B-内酰胺酶(ESBLs)菌株的体外抗菌活性,同时与不产ESBLs菌株进行对照。方法:采用纸片协同试验检测88株肺炎克雷伯菌与122株大肠埃希菌产ESBLs阳性率;并用K-B法对其进行抗菌药物敏感试验。结果:48株大肠埃希菌和34株肺炎克雷伯菌被确证产生ESBLs菌株,总阳性率为39.0%,产ESBLs菌株对多种常用抗菌药物产生了严重的耐药性,而亚胺培南对产ESBLs菌株保持了100%的敏感率。结论:临床微生物室对产ESBLs菌株仍应加强耐药性监测与公示,以指导临床合理用药。
OBJECTIVE: To investigate the in vitro antibacterial activity of 15 commonly used antimicrobial agents against extended-spectrum B-lactamase (ESBLs) -producing strains, and compare them with ESBLs-producing strains. Methods: The positive rates of ESBLs production in 88 strains of Klebsiella pneumoniae and 122 strains of Escherichia coli were detected by paper-plate synergistic test. Antibiotic susceptibility test was conducted by K-B method. Results: 48 strains of Escherichia coli and 34 strains of Klebsiella pneumoniae were confirmed to produce ESBLs strains, with a total positive rate of 39.0%. ESBLs-producing strains developed serious resistance to various commonly used antibiotics while imipenem Southern strains producing ESBLs maintained a 100% sensitivity. Conclusion: The monitoring and publicity of drug resistance should still be strengthened in ESBLs-producing strains in clinical microbiology laboratory to guide clinical rational drug use.